Vaginal adenocarcinoma
diseaseOn this page
Also known as adenocarcinoma of the vaginaadenocarcinoma of vaginavagina adenocarcinoma
Summary
Vaginal adenocarcinoma (MONDO:0020653) is a disease and 5 clinical trials. Top therapeutic interventions include cisplatin and triapine. A subtype of vaginal glandular neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | vaginal adenocarcinoma |
| Mondo ID | MONDO:0020653 |
| NCIT | C7981 |
| UMLS | C0279668 |
| MedGen | 124643 |
| GARD | 0025199 |
| Anatomy (UBERON) | UBERON:0000996 |
| Is cancer (heuristic) | no |
Also known as: adenocarcinoma of the vagina · adenocarcinoma of vagina · vagina adenocarcinoma · vaginal adenocarcinoma
Disease family
An umbrella term covering 1 Mondo subtype.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › vaginal disorder › vaginal neoplasm › vaginal glandular neoplasm › vaginal adenocarcinoma
Related subtypes (2): vaginal mullerian papilloma, vaginal adenoma
Subtypes (1): vaginal adenoid cystic carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 2 |
| PHASE3 | 1 |
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02466971 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers |
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT02595879 | PHASE1 | ACTIVE_NOT_RECRUITING | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer |
| NCT03452332 | PHASE1 | COMPLETED | Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers |
| NCT02140021 | Not specified | TERMINATED | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 2 |
| TRIAPINE | 3 | 2 |